Press Releases

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Posted on January 9, 2025

INOVIO Announces Pricing of $30 Million Public Offering

Posted on December 13, 2024

INOVIO Announces Proposed Public Offering

Posted on December 12, 2024

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Posted on December 3, 2024

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Posted on November 14, 2024

Immunology Data Shows INOVIO’s INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Posted on November 13, 2024

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

Posted on November 6, 2024

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Posted on October 21, 2024

INOVIO to Present at Upcoming Scientific Conferences

Posted on October 1, 2024

INOVIO to Present at Upcoming Scientific Conference

Posted on September 17, 2024

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.